» Articles » PMID: 30583514

Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

Overview
Date 2018 Dec 26
PMID 30583514
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS. CHIKV-NoLS-immunised mice developed long-term immunity from CHIKV infection after a single dose. To further evaluate CHIKV-NoLS attenuation and suitability as a vaccine, we examined the footpad of inoculated mice for underlying CHIKV-NoLS-induced immunopathology by histological and flow cytometric analysis. In comparison to CHIKV-WT-infected mice, CHIKV-NoLS-inoculated mice exhibited minimal inflammation and tissue damage. To examine the stability of attenuation, the plaque phenotype and replication kinetics of CHIKV-NoLS were determined following extended in vitro passage. The average plaque size of CHIKV-NoLS remained notably smaller than CHIKV-WT after extended passage and attenuated replication was maintained. To examine thermostability, CHIKV-NoLS was stored at 21 °C, 4 °C, -20 °C and -80 °C and infectious CHIKV-NoLS quantified up to 84 days. The infectious titre of CHIKV-NoLS remains stable after 56 days when stored at either -20 °C or -80 °C. Interestingly, unlike CHIKV-WT, the infectious titre of CHIKV-NoLS is not sensitive to freeze thaw cycles. These data further demonstrate preclinical safety and stability of CHIKV-NoLS.

Citing Articles

Long-Term Protection in Atlantic Salmon () to Pancreas Disease (PD) Can Be Achieved Through Immunization with Genetically Modified, Live Attenuated Salmonid Alphavirus 3.

Braaen S, Wessel O, Bjorgen H, Rimstad E Vaccines (Basel). 2025; 13(2).

PMID: 40006736 PMC: 11861613. DOI: 10.3390/vaccines13020190.


Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.

Shaikh M, Faiyazuddin M, Khan M, Pathan S, Syed I, Gholap A Front Microbiol. 2024; 15:1413250.

PMID: 39104592 PMC: 11298817. DOI: 10.3389/fmicb.2024.1413250.


Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development.

Hakim M, Aman A Viruses. 2023; 15(1).

PMID: 36680088 PMC: 9863735. DOI: 10.3390/v15010048.


Current Status of Chikungunya in India.

Front Microbiol. 2021; 12:695173.

PMID: 34262552 PMC: 8274422. DOI: 10.3389/fmicb.2021.695173.


Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.

Zhao Z, Deng Y, Niu P, Song J, Wang W, Du Y Front Immunol. 2021; 12:655743.

PMID: 33868299 PMC: 8044884. DOI: 10.3389/fimmu.2021.655743.


References
1.
Edelman R, Tacket C, Wasserman S, Bodison S, Perry J, Mangiafico J . Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2001; 62(6):681-5. DOI: 10.4269/ajtmh.2000.62.681. View

2.
Arankalle V, Shrivastava S, Cherian S, Gunjikar R, Walimbe A, Jadhav S . Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol. 2007; 88(Pt 7):1967-1976. DOI: 10.1099/vir.0.82714-0. View

3.
Tsetsarkin K, Vanlandingham D, McGee C, Higgs S . A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007; 3(12):e201. PMC: 2134949. DOI: 10.1371/journal.ppat.0030201. View

4.
Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin J . Clinical burden of chikungunya virus infection. Lancet Infect Dis. 2007; 8(1):2-3. DOI: 10.1016/S1473-3099(07)70294-3. View

5.
Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P . Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis. 2008; 8:99. PMC: 2528011. DOI: 10.1186/1471-2334-8-99. View